VINCIT: A Study of Visugromab for Cancer‑Associated Cachexia

Learning More About Cancer‑Associated Weight Loss and Muscle Loss 

The purpose of this study is to learn more about the experience of cancer‑associated cachexia, a condition in which individuals with certain cancers may experience unintentional weight loss, reduced appetite, and loss of muscle strength. Researchers are studying an investigational medication called Visugromab to better understand how people living with this condition are affected over time and what biological factors may influence changes in weight, appetite, and physical functioning. Cancer‑associated cachexia can impact daily activities, quality of life, and the overall treatment experience. Through this study, researchers aim to gather information about how this condition progresses, how individuals describe their symptoms, and how supportive‑care approaches may differ when evaluated in a structured research setting. The study uses a randomized, double‑blind, placebo‑controlled design to support objective scientific understanding of cachexia in adults with cancer.

 

Disclaimer: This summary is provided solely for informational purposes. It does not invite participation, offer medical advice, or suggest that any investigational medication is safe, effective, or available as treatment. Individuals seeking guidance about cancer‑related weight or muscle changes should consult their healthcare provider.